Tumor antigen-primed CD8 T cells differentiate into effector T cells that kill tumor cells rapidly, whereas durable responses of CD8 T cells are required to cope with long-lasting tumor growth. However, it is not well known how persisting CD8 T cells are generated. In this study, we analyzed CD8 T cells primed by antigens in tumor-draining lymph nodes and found that CD8 T cells first differentiated into a CD62L-intermediate (CD62Lint) stage upon antigen stimulation. These cells gave rise to tumor-infiltrating CD62L-CD44high Bcl6- effector T cells and CD62L+CD44highBcl6+ memory-like T cells. Memory-like T cells within the tumor expressed CD127, CXCR3 and had the potential to proliferate significantly when they were transferred into tumor-bea...
Whereas preclinical investigations and clinical studies have established that CD8(+) T cells can pro...
International audienceRegulatory T-cells (Tregs) are crucial for the maintenance of immune tolerance...
Adoptive transfer of tumor-reactive T cells (ACT) is an effective therapy for patients with aggressi...
Tissue resident memory (Trm) CD8 T cells infiltrating tumors represent an enriched population of tum...
Increasing the efficacy of adoptively transferred, tumor antigen specific T cells is a major goal of...
Improving the efficacy of immune checkpoint therapies will require a better understanding of how imm...
The implantation of cancer cell lines into immunocompetent mice acts as a vaccination event, resulti...
Cytotoxic T lymphocytes (CTL) from CD8β-deficient mice have powerful FasL-mediated cytotoxicity and ...
Although there has been extensive research on T-cell responses to cancer immunotherapy, the understa...
How tumor-infiltrating lymphocytes (TILs) that are tumor-specific but functionally tolerant persist ...
Classically, memory T cells arise from naive T cells after a productive immune response to a foreign...
Adoptive cell immunotherapy using in vitro expanded autologous tumor-infiltrating lymphocytes has th...
Following initial therapy responses, tumors often relapse leading to patient mortality. How cancer c...
Purpose Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tiss...
It has been proposed that a self-renewing, “stem-cell” like stage of CD8+ T cell development exists ...
Whereas preclinical investigations and clinical studies have established that CD8(+) T cells can pro...
International audienceRegulatory T-cells (Tregs) are crucial for the maintenance of immune tolerance...
Adoptive transfer of tumor-reactive T cells (ACT) is an effective therapy for patients with aggressi...
Tissue resident memory (Trm) CD8 T cells infiltrating tumors represent an enriched population of tum...
Increasing the efficacy of adoptively transferred, tumor antigen specific T cells is a major goal of...
Improving the efficacy of immune checkpoint therapies will require a better understanding of how imm...
The implantation of cancer cell lines into immunocompetent mice acts as a vaccination event, resulti...
Cytotoxic T lymphocytes (CTL) from CD8β-deficient mice have powerful FasL-mediated cytotoxicity and ...
Although there has been extensive research on T-cell responses to cancer immunotherapy, the understa...
How tumor-infiltrating lymphocytes (TILs) that are tumor-specific but functionally tolerant persist ...
Classically, memory T cells arise from naive T cells after a productive immune response to a foreign...
Adoptive cell immunotherapy using in vitro expanded autologous tumor-infiltrating lymphocytes has th...
Following initial therapy responses, tumors often relapse leading to patient mortality. How cancer c...
Purpose Resident memory CD8 T cells, owing to their ability to reside and persist in peripheral tiss...
It has been proposed that a self-renewing, “stem-cell” like stage of CD8+ T cell development exists ...
Whereas preclinical investigations and clinical studies have established that CD8(+) T cells can pro...
International audienceRegulatory T-cells (Tregs) are crucial for the maintenance of immune tolerance...
Adoptive transfer of tumor-reactive T cells (ACT) is an effective therapy for patients with aggressi...